Indoco Remedies

Indoco Remedies Forward P/E

The Forward P/E Ratio of Indoco Remedies (INDOCO.NS) as of Oct 21, 2026 is -18.91. In the previous year, Forward P/E Ratio was -25.31 — a change of -25.29% (higher).

Forward P/E

-18.91

YoY

-25.29%

Last updated:

Forward P/E Ratio of Indoco Remedies is 2026 -18.91 . Forward P/E Ratio of Indoco Remedies was 2025 -25.31 . It decreases by -25.29% higher compared to the previous year.

The Indoco Remedies Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2019
-642.78 INR
Jan 1, 2020
77.40 INR
Jan 1, 2021
20.06 INR
Jan 1, 2022
12.06 INR
Jan 1, 2023
13.12 INR
Jan 1, 2024
18.96 INR
Jan 1, 2025
-25.31 INR
Jan 1, 2026
-18.91 INR
The Indoco Remedies Forward P/E history
YEARForward P/EYoY
-18.91-25.29%
-25.31-233.52%
18.96+44.47%
13.12+8.82%
12.06-39.89%
20.06-74.08%
77.40-112.04%
-642.78-1,517.39%
45.35+87.22%
24.22+7.68%
22.49-0.20%
22.54-29.98%
32.19—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Indoco Remedies Stock analysis

What does Indoco Remedies do? Indoco Remedies Ltd. manufactures and markets formulations and active pharmaceutical ingredients, offering medicines across therapeutic categories like diabetology, respiratory, and women's health. Its product portfolio includes brands such as Cyclopam, Sensodent-K, Karvol Plus, and Rexidin M, targeting both domestic and international markets. The company serves healthcare providers and consumers through its extensive range of pharmaceutical products, with subsidiaries supporting its global operations. The firm's revenue streams derive from the sale of finished dosage forms and APIs, with key brands like Cital UTI and Kidodent catering to specific medical needs. International markets represent a significant segment, complementing domestic sales, while subsidiaries such as Indoco Remedies Czech sro and Indoco Remedies UK Limited facilitate regional distribution and market expansion. Products like Lignox A and Homide are positioned for niche therapeutic applications, driving demand among healthcare professionals and patients. Indoco Remedies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Indoco Remedies stock

Forward P/E Ratio of Indoco Remedies is -18.91 in 2026.

Forward P/E Ratio of Indoco Remedies changed from -25.31 to -18.91, representing a -25.29% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Indoco Remedies since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Indoco Remedies with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Indoco Remedies

All Key Metrics — Indoco Remedies